Benefits of the MEDPED treatment support program for patients with familial hypercholesterolemia

Journal of Clinical Lipidology

Volumn 3, Issue 2, 2009, Pages 94-100

  Stephenson, Susan Huckendubler ^a   Larrinaga Shum, Stacey ^a   Hopkins, Paul N ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Cholesterol intervention; Education; Familial hypercholesterolemia; Prevention

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG MEGADOSE; DRUG USE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT EDUCATION; PATIENT GUIDANCE; PATIENT MONITORING; PRIORITY JOURNAL; QUESTIONNAIRE; REGISTER; SELF REPORT;

EID: 62549112238     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2009.02.004     Document Type: Article

References (38)

1. Pearson T.A., Laurora I., Chu H., et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160 (2000) 459-467
2. Davidson M.H., Maki K.C., Pearson T.A., et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 96 (2005) 556-563
3. Primatesta P., and Poulter N.R. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 321 (2000) 1322-1325
4. Mantel-Teeuwisse A.K., Verschuren W.M., Klungel O.H., et al. Undertreatment of hypercholesterolaemia: a population-based study. Br J Clin Pharmacol 55 (2003) 389-397
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
6. Grundy S.M., Cleeman J.I., Merz C.N., et al. A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 24 (2004) 1329-1330
7. Watts G.F., Lewis B., and Sullivan D.R. Familial hypercholesterolemia: a missed opportunity in preventive medicine. Nat Clin Pract Cardiovasc Med 4 (2007) 404-405
8. Williams R.R., Schumacher M.C., Barlow G.K., et al. Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah. Am J Cardiol 72 suppl (1993) 18D-24D
9. Umans-Eckenbausen M.A.W., Defesche J.C., Sijbrands E.J., et al. Review of first 5 years of screening for familial hypercholesterolemia in the Netherlands. Lancet 357 (2001) 165-168
10. Neil H.A., Hammond T., Huxley R., et al. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 321 (2000) 148
11. Avis H.J., Vissers M.N., Stein E.A., et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 27 (2007) 1803-1810
12. Arambepola C., Farmer A.J., Perera R., et al. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. Atherosclerosis 195 (2007) 339-347
13. Rodenburg J., Vissers M.N., Wiegman A., et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 116 (2007) 664-668
14. Kavey R.E., Allada V., Daniels S.R., et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association expert panel on population and prevention science; the councils on cardiovascular disease in the young, epidemiology and prevention, nutrition, physical activity and metabolism, high blood pressure research, cardiovascular nursing, and the kidney in heart disease; and the interdisciplinary working group on quality of care and outcomes research: endorsed by the American Academy of Pediatrics. Circulation 114 (2006) 2710-2738
15. McCrindle B.W., Urbina E.M., Dennison B.A., et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 115 (2007) 1948-1967
16. Fonarow G.C., Gawlinski A., Moughrabi S., et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 87 (2001) 819-822
17. Lacy C.R., Suh D.C., Barone J.A., et al. Impact of a targeted intervention on lipid-lowering therapy in patients with coronary artery disease in the hospital setting. Arch Intern Med 162 (2002) 468-473
18. Carson J.J. Pharmacist-coordinated program to improve use of pharmacotherapies for reducing risk of coronary artery disease in low-income adults. Am J Health Syst Pharm 56 (1999) 2319-2324
19. Harris D.E., Record N.B., Gipson G.W., et al. Lipid lowering in a multidisciplinary clinic compared with primary physician management. Am J Cardiol 81 (1998) 929-933
20. Bogden P.E., Koontz L.M., Williamson P., et al. The physician and pharmacist team. An effective approach to cholesterol reduction. J Gen Intern Med 12 (1997) 158-164
21. DeBusk R.F., Miller N.H., Superko H.R., et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med 120 (1994) 721-729
22. Merenich J.A., Lousberg T.R., Brennan S.H., et al. Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente experience). Am J Cardiol 85 (2000) 36A-42A
23. Williams R.R., Hamilton-Craig I., Costner G.M., et al. MED-PED: An integrated genetic strategy for preventing early deaths. In: Berg K., Boulyjenkov V., and Christen Y. (Eds). Genetic approaches to noncommunicable diseases (1996), Springer-Verlag, Heidelberg 35-45
24. Williams R.R., Hopkins P.N., Stephenson S., et al. Primordial prevention of cardiovascular disease through applied genetics. Prev Med 29 (1999) S41-S49
25. Hayden M.R., and Josephson R. Development of a program for identification of patients with familial hypercholesterolemia in British Columbia: a model for prevention of coronary disease. Am J Cardiol 72 suppl (1993) 25D-29D
26. Kotze M.J., and Callis M. MEDPED FH: a paradigm for other common monogenic diseases in South Africa. Atherosclerosis 144 (1999) 467-468
27. Schmidt H., and Kostner G.M. Familial hypercholesterolemia in Austria reflects the multi-ethnic origin of our country. Atherosclerosis 148 (2000) 431-432
28. World Health Organization Familial Hypercholesterolemia Consultation Group. Familial Hypercholesterolemia. Report of a WHO Consultation (October 3, 1997), World Health Organization, Paris 1998. WHO/HGN/FH/CONS/98.7
29. Williams R.R., Hunt S.C., Schumacher M.C., et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 72 (1993) 171-176
30. Roberts W.C. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 80 (1997) 106-107
31. Goldstein J.L., Hobbs H.H., and Brown M.S. Familial hypercholesterolemia. In: Scriver C.R., Beaudet A.L., Sly W.S., et al. (Eds). The metabolic and molecular bases of inherited disease (1995), McGraw-Hill, New York 1981-2030
32. Heath K.E., Gahan M., Whittall R.A., et al. Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis. Atherosclerosis 154 (2001) 243-246
33. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
34. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
35. Kane J.P., Malloy M.J., Ports T.A., et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264 (1990) 3007-3012
36. Thompson G.R., Maher V.M.G., Matthews S., et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet 345 (1995) 811-816
37. Leren T.P. Cascade genetic screening for familial hypercholesterolemia. Clin Genet 66 (2004) 483-487
38. Hopkins P.N. Familial hypercholesterolemia-improving treatment and meeting guidelines. Int J Cardiol 89 (2003) 13-23